BioCardia Inc Stock Nasdaq
Equities
US09060U1016
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
May. 21 | BioCardia to Implement 1-for-15 Reverse Stock Split; Shares Fall After Hours | MT |
May. 14 | Transcript : BioCardia, Inc., Q1 2024 Earnings Call, May 14, 2024 |
Financials (USD)
Sales 2022 | 1.35M | Sales 2023 | 477K | Capitalization | 15.69M |
---|---|---|---|---|---|
Net income 2022 | -11M | Net income 2023 | -11M | EV / Sales 2022 | 26.7 x |
Net cash position 2022 | 5.73M | Net Debt 2023 | 212K | EV / Sales 2023 | 33.3 x |
P/E ratio 2022 |
-3.11
x | P/E ratio 2023 |
-1.22
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 70.52% |
Latest transcript on BioCardia Inc
Managers | Title | Age | Since |
---|---|---|---|
Peter Altman
CEO | Chief Executive Officer | 57 | 01-12-31 |
David McClung
DFI | Director of Finance/CFO | 61 | 13-08-31 |
Chief Tech/Sci/R&D Officer | - | 17-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Simon Stertzer
BRD | Director/Board Member | 88 | 01-12-31 |
Jay Moyes
BRD | Director/Board Member | 70 | 10-12-31 |
Richard Krasno
BRD | Director/Board Member | 82 | 16-10-23 |
1st Jan change | Capi. | |
---|---|---|
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |